Eric Sonnier Email & Phone Number

United States

Strategic account management and access with LUGPA clinics, IDNs, NCCN/NCI institutions, academic institutions and oncology clinics within the assigned territory of Northern and Southwest Louisiana. Compliantly executed effective operational processes for accounts to identify appropriate patients for treatment of advanced prostate cancer with Erleada (Apalutamide) and metastatic urothelial carcinoma with Balversa (Erdafitinib). Analyzed account performance, identified prescriber adoption barriers and proposed solutions to address the barriers. Apply business acumen to generate prescriber segmentation data and identify key influencers to customize account strategy plans.

Develop and manage account relationships with targeted integrated delivery network institutions and community accounts through product promotion of Eisai’s solid tumor product for metastatic breast cancer, Halaven (Eribulin). Provide clinical, efficacy and safety information on Halaven to key treatment providers, Pathway/P&T committee members and C-suite employees within accounts. Evaluate the needs of the accounts and work with National and Regional Business Leaders, Managed Markets Medical, HEOR, and Marketing to develop tactical strategies to support account needs. Managed contract strategy with purchasing departments, pharmacies and decision makers. Territory included Mississippi, Louisiana, Arkansas, Missouri, Texas and Oklahoma.

Responsible for product promotion, education and account management of the Lilly Oncology Solid Tumor GI buy and bill portfolio. Key business relationships built within the medical oncology therapeutic area. Crucial accounts included hospitals, IDNs, teaching institutions and community practitioners. Exceeded sales goals through detailing clinical trial data and product/label updates for Erbitux (Cetuximab) and Cyramza (Ramucirumab). Engaged in disease state and product promotion at Regional and National conferences (FLASCO, State of the Summit, Great Debates, ONS, ASCO/ESMO)• Top 5 combined product revenue nationally to date 2021• Advisory Council Leader 2021• National Delegate for ASCO Convention 2021• Top 10 combined product revenue nationally for 2020

Lafayette, Louisiana Area

Responsible for the promotion of Zubsolv (Buprenorphine) to key addiction/pain prescribers in Louisiana. Call points include inpatient detox units, behavioral health units and outpatient programs. Specialists include psychiatrists, oncologists, emergency medicine and general practice physicians.• District Training Mentor-Southeast Region 2019• President’s Circle of Excellence for 2018• Member of National Best Practices Team 2018• Convention Delegate for 2018

Lafayette, Louisiana Area

Developed a new customer base for safety, industrial maintenance, repair and operations (MRO) products and services to hospitals, industrial plants, OEM/production facilities, manufacturing plants, and oilfield service companies. Responsible for initiating sales presentations, implementing account contracts, identifying customer needs and addressing those needs with cost effective solutions.

Lafayette, Louisiana Area

Launched Vascepa, for the treatment of hypertryglyceridemia to key cardiologists, endocrinologists and primary care physicians in Southwest Louisiana. Laid off in September 2013

Lafayette, Louisiana Area

Developed territory sales and marketing plans to achieve and exceed goals. Responsible for attracting new business through superior customer service and collaborative working relationships. Physicians include specialists such as cardiology, neurology, oncology, psychiatrists, physical medicine/rehab and primary care physicians

Successfully launched Silenor to specialists and general practice physicians in Southwest Louisiana. Physicians targets included, sleep medicine, psychiatrists, pain management, physical medicine/rehab, oncology, cardiology, neurology, internal medicine and family practice.

Launched and marketed Opana ER (Oxymorphone), Lidoderm (Lidocaine 5%) and Frova (Frovatriptan) to influential pain management, oncology and neurology clinics in Louisiana and Texas.Launched Opana ER to realize a leading market share of 18%Consistent Top 20 regional and national product rankings for the past four years2010: 1st in the nation for Frova sales2009: 1 of only 19 reps in region with 2 products above 100% sales forecast2008: 8th in nation for Frova sales and 30th in the nation for all three products2007: Regional top 10 for Opana ER and National top 20 for Frova sales

Successfully fostered relationships with key neurologist, allergy/immunologists and pulmonologists to increase market penetration of Astelin, Optivar and Zomig. Territory included all of Southwest Louisiana and Southeast Texas.Presidents Club Top 20 ranking for 2004

Promoted and sold extensive financial services products to individuals and to corporations.Accomplishments:Conducted the planning of personal financial statements and the allocation of resources into the selected insurance and security instruments.

Successfully executed product promotion and managed territory business development of Zomig (Zolmitriptan), Nexium (Esomeprazole), Accolate (Zafirlukast), Pulmicort (Budesonide), Zestril (Lisinopril), and Sular (Nisoldipine) to therapeutic specialists such as: neurology, gastroenterology, allergy/immunology, pulmonology, cardiology, and primary care within the institutional and community markets. Successfully launched Rhinocort AQ (Budesonide) to Allergy/Immunology specialists. Hospital Environment and Flexible Selling Sales certified. • Regional Top Ten Performance Index: 2002 • Zomig Champion/Sales Leader: 2000, 2002 • Member of Nashville Region Support Team• District Training Champion Team: 2001 • Regional Trainer: 2001 • Twelfth in nation for Accolate market share vs. Singulair in 2000• Top National Market Share Rhinocort AQ launch: 2000 • National Senior Class Training Advisor and National Conventions Delegate:1999

Taught Contemporary Biology and Molecular Biology Labs to approximately 75 undergraduates per semester. In addition, carried out research in molecular biology, specifically investigating the involvement of particular genes in cell division control.

Molecular Biology, 3.6

B.S, Zoology

Education record

Pursued Master'S Degree, Cell And Molecular Biology

Activities and Societies: Member of the American Association for Advancement of Science Member of Alpha Theta Epsilon Honor Society Member.